(Q37572952)

21 August 2017

0 references

1 reference

title

Weight gain in antipsychotic-naive patients: a review and meta-analysis (English)

1 reference

21 August 2017

0 references

0 references

1 reference

I Tarricone

1

0 references

author name string

B Ferrari Gozzi

2

1 reference

21 August 2017

A Serretti

3

1 reference

21 August 2017

D Grieco

4

1 reference

21 August 2017

D Berardi

5

1 reference

21 August 2017

language of work or name

English

0 references

publication date

6 August 2009

1 reference

21 August 2017

Psychological Medicine

1 reference

21 August 2017

40

1 reference

21 August 2017

2

1 reference

21 August 2017

187-200

1 reference

Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.

21 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Pharmacological treatments for first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Meta-analysis of genetic association studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

First-episode schizophrenia: a focus on pharmacological treatment and safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Weight gain: side effect of atypical neuroleptics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Glucose intolerance with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Differential metabolic effects of antipsychotic treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Atypical antipsychotics and weight gain--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Metabolic side effects of second generation antipsychotic agents in antipsychotic-naïve patients: one-month prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Abnormal glucose metabolism in patients treated with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

https://api.crossref.org/works/10.1017%2FS0033291709990407

1 reference

7 January 2021

The unhealthy lifestyle of people with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

Weight gain in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

Predictors of noncompliance in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709990407

7 January 2021

10.1017/S0033291709990407

Identifiers

DOI

1 reference

21 August 2017

1 reference